Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fezakinumab in Rheumatoid Arthritis
NCT00883896Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2009
- Primary completion
- Feb 2011
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of fezakinumab in rheumatoid arthritis (RA) (5 arms), sponsored by Pfizer. Primary endpoint: American College of Rheumatology 20 Percent Response at 12 weeks. Started Jun 2009; status: completed.
02
Drugs
fezakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00883896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883896.